Silverfin false false 30/04/2026 01/05/2025 30/04/2026 Paul Mart Kirkland 19/04/2007 06 August 2026 The principal activity of the Company during the financial year was that of specialist ear, nose and throat treatment for adults. 06220144 2026-04-30 06220144 bus:Director1 2026-04-30 06220144 2025-04-30 06220144 core:CurrentFinancialInstruments 2026-04-30 06220144 core:CurrentFinancialInstruments 2025-04-30 06220144 core:ShareCapital 2026-04-30 06220144 core:ShareCapital 2025-04-30 06220144 core:RetainedEarningsAccumulatedLosses 2026-04-30 06220144 core:RetainedEarningsAccumulatedLosses 2025-04-30 06220144 core:FurnitureFittings 2025-04-30 06220144 core:ComputerEquipment 2025-04-30 06220144 core:FurnitureFittings 2026-04-30 06220144 core:ComputerEquipment 2026-04-30 06220144 core:CostValuation 2025-04-30 06220144 core:RevaluationsIncreaseDecreaseInInvestments 2026-04-30 06220144 core:CostValuation 2026-04-30 06220144 bus:OrdinaryShareClass1 2026-04-30 06220144 2025-05-01 2026-04-30 06220144 bus:FilletedAccounts 2025-05-01 2026-04-30 06220144 bus:SmallEntities 2025-05-01 2026-04-30 06220144 bus:AuditExemptWithAccountantsReport 2025-05-01 2026-04-30 06220144 bus:PrivateLimitedCompanyLtd 2025-05-01 2026-04-30 06220144 bus:Director1 2025-05-01 2026-04-30 06220144 core:FurnitureFittings core:TopRangeValue 2025-05-01 2026-04-30 06220144 core:ComputerEquipment core:TopRangeValue 2025-05-01 2026-04-30 06220144 2024-05-01 2025-04-30 06220144 core:FurnitureFittings 2025-05-01 2026-04-30 06220144 core:ComputerEquipment 2025-05-01 2026-04-30 06220144 bus:OrdinaryShareClass1 2025-05-01 2026-04-30 06220144 bus:OrdinaryShareClass1 2024-05-01 2025-04-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 06220144 (England and Wales)

THE ENT CLINIC LIMITED

Unaudited Financial Statements
For the financial year ended 30 April 2026
Pages for filing with the registrar

THE ENT CLINIC LIMITED

Unaudited Financial Statements

For the financial year ended 30 April 2026

Contents

THE ENT CLINIC LIMITED

STATEMENT OF FINANCIAL POSITION

As at 30 April 2026
THE ENT CLINIC LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 30 April 2026
Note 2026 2025
£ £
Fixed assets
Tangible assets 3 1,203 186
Investments 4 169,345 153,435
170,548 153,621
Current assets
Debtors 5 31,818 27,495
Cash at bank and in hand 33,366 52,714
65,184 80,209
Creditors: amounts falling due within one year 6 ( 38,261) ( 42,794)
Net current assets 26,923 37,415
Total assets less current liabilities 197,471 191,036
Provision for liabilities ( 301) ( 47)
Net assets 197,170 190,989
Capital and reserves
Called-up share capital 7 1,000 1,000
Profit and loss account 196,170 189,989
Total shareholder's funds 197,170 190,989

For the financial year ending 30 April 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of The ENT Clinic Limited (registered number: 06220144) were approved and authorised for issue by the Director on 06 August 2026. They were signed on its behalf by:

Paul Mart Kirkland
Director
THE ENT CLINIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2026
THE ENT CLINIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

The ENT Clinic Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Sussex Premier Health, The Ridge, St. Leonards-On-Sea, TN37 7RE, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Statement of Financial Position date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Statement of Financial Position date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Fixtures and fittings 4 years straight line
Computer equipment 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings.

Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

2. Employees

2026 2025
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Tangible assets

Fixtures and fittings Computer equipment Total
£ £ £
Cost
At 01 May 2025 160 3,887 4,047
Additions 0 1,303 1,303
Disposals 0 ( 2,558) ( 2,558)
At 30 April 2026 160 2,632 2,792
Accumulated depreciation
At 01 May 2025 160 3,701 3,861
Charge for the financial year 0 286 286
Disposals 0 ( 2,558) ( 2,558)
At 30 April 2026 160 1,429 1,589
Net book value
At 30 April 2026 0 1,203 1,203
At 30 April 2025 0 186 186

4. Fixed asset investments

Listed investments Total
£ £
Cost or valuation before impairment
At 01 May 2025 153,435 153,435
Movement in fair value 15,910 15,910
At 30 April 2026 169,345 169,345
Carrying value at 30 April 2026 169,345 169,345
Carrying value at 30 April 2025 153,435 153,435

5. Debtors

2026 2025
£ £
Trade debtors 18,343 17,496
Amounts owed by director 9,999 9,999
Prepayments 3,476 0
31,818 27,495

6. Creditors: amounts falling due within one year

2026 2025
£ £
Accruals 10,042 8,938
Taxation and social security 28,219 33,856
38,261 42,794

7. Called-up share capital

2026 2025
£ £
Allotted, called-up and fully-paid
1,000 Ordinary A shares of £ 1.00 each 1,000 1,000

8. Related party transactions

Transactions with the entity's director

At the balance sheet date £9,999 was owed to the company by the director (2025: £9,999).